NEW YORK, March 19 - Australian proteomics company Proteome Systems together with the Cystic Fibrosis Foundation will collaborate to probe the proteins involved in cystic fibrosis.
The partnership, announced on Monday, would look for new drug targets and new methods to monitor disease progression.
Under the deal, The Cystic Fibrosis Foundation Therapeutics, the foundation's nonprofit affiliate, will retain exclusive rights to develop new therapeutic candidates. Proteome Systems, meanwhile, will have rights to develop diagnostic and prognostic applications. The partners will share rights to develop non-CF related products.
Specifically, the collaboration seeks to identify protein-expression patterns in sputum and lung secretions with the goal of preventing or slowing the progression of the disease. The foundation said that identifying CF biomarkers could also greatly accelerate the progress of clinical trials and act as a guide in clinical practice.
The CFFT guides drug discovery and evaluation for the Cystic Fibrosis Foundation. CF foundation efforts include a CF-focused bioinformatics center at the University of North Carolina, Chapel Hill and an Affymetrix whole-genome microarray of Pseudomonas aeruginosa, the bacteria that can cause chronic lung infections in CF patients.
Proteome Systems conducts its own proteomics research and is also developing a proteomics analysis platform, ProteomIQ. Established in 1999, the company has labs in Sydney and in Boston.